与米索普罗斯托尔相关的有毒表皮解:一个案例报告
Okbu Frezgi1, Mulugeta Russom2,3,4
1Gynecology and Obstetric Unit, Orotta College of Medicine and Health Sciences, Asmara, Eritrea.
International medical case reports journal
|June 30, 2023
概括
一个罕见的有毒表皮解病例,一种严重的皮肤反应,是在一个患者使用弥索普罗来终止怀孕后观察到的. 需要进一步的研究来确认是否能引起这种严重的不良影响.
科学领域:
- 药物监督 药物监督 药物监督
- 皮肤病学 皮肤病学
- 生殖医学 生殖医学
背景情况:
- 弥索普罗斯托尔是一种前列腺素E1模拟物,广泛用于医疗终止妊娠.
- 监管机构提供的当前产品信息没有列出严重的粘膜皮肤反应,如有毒的表皮解,作为已知的mizoprostol的不良影响.
- 这一案例突出了对mizoprostol的潜在,未经记录的不良反应.
研究的目的:
- 报告一种可能与mizoprostol使用相关的有毒表皮解病例.
- 为了提高人们对米索普罗斯托尔可能存在的严重不良影响的认识,这些不良影响以前没有被记录下来.
- 建议需要进一步调查mizoprostol的安全性.
主要方法:
- 一份病例报告,详细介绍了一名患有毒性表皮解的患者的临床表现和治疗.
- 审查患者的病史和药物治疗,排除其他潜在原因.
- 评估mizoprostol与不良事件之间的因果关系.
主要成果:
- 一名25岁的妇女在因流产管理错误而接受三剂米索普罗斯托尔 (每剂200毫克) 后发生了有毒的表皮解.
- 没有发现其他致病原体.
- 患者在治疗后四周内完全康复.
结论:
- 毒性表皮消亡是mizoprostol可能的副作用,尽管目前的药物信息中没有列出它.
- 这一案例强调了药物监测对于识别罕见药物不良反应的重要性.
- 需要进一步的流行病学研究来确定确切的联系,并了解这种反应的发生率.
相关概念视频
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
507
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
507
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
205
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
205
01:26Peptic Ulcer Disease IV: Management
113
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
113
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
223
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
223
01:26Toxic Reactions: Overview
1.0K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.0K
01:16Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K